The U.S. nicotine pouch market is getting another major shake-up after the Food and Drug Administration authorized several new products from two established brands.
The latest decisions cover 11 ZYN ULTRA nicotine pouches from Swedish Match USA and four on! nicotine pouch products from Helix Innovations. Together, the authorizations add more nicotine strengths and flavor choices to a category that has grown increasingly prominent among people looking for alternatives to traditional tobacco products.
The FDA’s decisions are also significant because they show how the agency is continuing to approach nicotine pouches through the premarket tobacco application process.
ZYN ULTRA Adds Higher Nicotine Options
The newest ZYN authorization centers on the ZYN ULTRA line, which includes products containing 9 mg of nicotine and one 11 mg option.
The authorized flavors include Chill, Citrus, Cool Mint, Deep Freeze, Menthol, Peppermint, Smooth, Spearmint, Wintergreen Chill, and Wintergreen. Smooth is available in both 9 mg and 11 mg versions.
That gives consumers more choices within the ZYN lineup, particularly for those looking for stronger nicotine formulations.
The FDA authorized the products on August 21, 2026, following review under the agency’s premarket tobacco product application pathway.
The decision does not mean the products are considered safe or “FDA approved.” The FDA specifically distinguishes marketing authorization from approval and continues to emphasize that tobacco products can be harmful and addictive.
on! Brings More Lower-Strength Choices
The ZYN decision came shortly after another FDA action involving Helix Innovations and its on! nicotine pouch brand.
On August 4, the agency authorized four new products: Rich Berry in 2 mg, Cappuccino in both 2 mg and 4 mg, and Autumn Spice in 2 mg.
The additions give the on! lineup a broader mix of flavor profiles, ranging from fruit to coffee-inspired and seasonal options.
The lower nicotine strengths also create more variety for consumers who are interested in nicotine pouches without choosing some of the higher-strength products available elsewhere in the category.
That combination of different strengths and flavors has become an important part of the pouch market. Instead of competing only around nicotine delivery, manufacturers are increasingly using flavor variety and product design to distinguish different offerings.
FDA Looks Beyond the Number on the Can
One important part of the FDA’s review process is that nicotine concentration is not the agency’s only consideration.
The FDA evaluates how a product is designed and formulated, along with materials and other characteristics that can influence how much nicotine reaches the body and how quickly it is delivered.
That means two products with similar labeled nicotine levels can still receive different regulatory evaluations based on their overall characteristics.
The agency also examines the levels of harmful and potentially harmful constituents associated with the products.
For the newly authorized nicotine pouches, the FDA determined that the products contained lower levels of most harmful and potentially harmful constituents compared with other oral and smokeless tobacco products. Some constituents were present at levels too low to quantify.
The Switching Question Remains Important
The FDA’s decisions are based partly on the potential population-level impact of authorized products.
For people who already smoke cigarettes or use smokeless tobacco, completely switching to an FDA-authorized nicotine pouch can reduce exposure to many harmful chemicals compared with continuing to use those traditional tobacco products.
The word “completely” matters.
The FDA has pointed out that using nicotine pouches while continuing to smoke does not provide the same level of potential risk reduction as switching completely away from combustible tobacco.
That distinction is likely to remain an important part of the broader conversation surrounding nicotine pouches as the category continues to expand.
A Faster Regulatory Process Is Taking Shape
The recent authorizations also highlight the FDA’s nicotine pouch pilot program.
The agency created the program to make the review of certain premarket applications more efficient. According to the FDA, the pilot has helped speed up the resolution of outstanding issues, reduce response times for deficiency letters, and make parts of the scientific review process more efficient.
The agency has said that lessons learned from the pilot could be applied to other premarket tobacco product applications.
That could have broader consequences for manufacturers waiting for regulatory decisions.
The Authorized Market Keeps Growing
Following the latest ZYN ULTRA decision, the FDA said 43 nicotine pouch products had received marketing authorization in the United States. Twenty-three of those products had been authorized through the pilot program.
The growing number of authorized products gives consumers more options while also establishing a clearer regulatory distinction between products that have completed the FDA’s premarket process and those that have not.
The agency has also made clear that nicotine pouches without the required marketing authorization can face enforcement action.
What the New Products Mean for the Category
The newest ZYN and on! authorizations suggest that the nicotine pouch market is moving toward greater variety rather than simply more products.
Higher-strength options are appearing alongside lower-strength formulations, while flavor selections continue expanding beyond traditional mint and wintergreen profiles.
At the same time, the FDA’s decisions demonstrate that authorization depends on more than popularity or consumer demand. Product formulation, nicotine delivery, constituent levels, and potential effects on both current tobacco users and non-users all factor into the agency’s evaluation.
For nicotine pouch manufacturers, that makes regulatory strategy increasingly important.
For consumers, the latest decisions mean more products are entering the authorized U.S. market, but the FDA’s message remains consistent: marketing authorization does not make a nicotine product harmless, and nicotine remains addictive.
